Infinity To Participate In Three June Investor Conferences
Get Alerts INFI Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass., May 31, 2016 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that management will present at the following investor conferences:
- Jefferies Healthcare Conference, New York, June 7th at 1:30 p.m. ET
- William Blair Annual Growth Stock Conference, Chicago, June 14th at 9:30 a.m. CT (10:30 a.m. ET)
- JMP Securities Life Sciences Conference, New York, June 21st at 4:30 p.m. ET
A live webcast of these presentations will be accessible on the Investors/Media section of Infinity's website at www.infi.com, and will be available for 30 days following each event.
About Infinity Pharmaceuticals, Inc. Infinity is an innovative biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to people with difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. For more information on Infinity, please refer to the company's website at www.infi.com.
Contact: Christi Waarich Senior Manager, Investor Relations 617-453-1363 or [email protected]
Logo - http://photos.prnewswire.com/prnh/20150916/267365LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/infinity-to-participate-in-three-june-investor-conferences-300277088.html
SOURCE Infinity Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldgroup Mining and Gold Resource Corporation Announce Expected Ticker Symbol of Combined Company
- Teekay Group Publishes 2025 Sustainability Report
- Precipitate Gold Strengthens Board with Appointment of Dominican Business Leader Pelayo Troncoso and Mining Finance Executive John Wenger
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
William Blair, Jefferies & Co, JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share